{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:09:56Z","timestamp":1787497796287,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["21 0401 FE"],"award-info":[{"award-number":["21 0401 FE"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["2019\/0081"],"award-info":[{"award-number":["2019\/0081"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["21 1749 PJ"],"award-info":[{"award-number":["21 1749 PJ"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ejca.2022.01.016","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T06:51:32Z","timestamp":1645944692000},"page":"128-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial"],"prefix":"10.1016","volume":"168","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-3637","authenticated-orcid":false,"given":"Aglaia","family":"Schiza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8482-2674","authenticated-orcid":false,"given":"Viktoria","family":"Thurfjell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3652-3706","authenticated-orcid":false,"given":"Axel","family":"Stenmark Tullberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Olofsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-4550","authenticated-orcid":false,"given":"Erik","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1210-5961","authenticated-orcid":false,"given":"Patrick","family":"Micke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4841-2672","authenticated-orcid":false,"given":"Per","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6274-2435","authenticated-orcid":false,"given":"Fredrik","family":"W\u00e4rnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-7256","authenticated-orcid":false,"given":"Carina","family":"Strell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2022.01.016_bib1","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1080\/0284186X.2016.1211317","article-title":"A validation of DCIS registration in a population-based breast cancer quality register and a study of treatment and prognosis for DCIS during 20 years","volume":"55","author":"Wadsten","year":"2016","journal-title":"Acta Oncol"},{"issue":"41","key":"10.1016\/j.ejca.2022.01.016_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","article-title":"Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast","volume":"2010","author":"Early Breast Cancer Trialists' Collaborative","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"4","key":"10.1016\/j.ejca.2022.01.016_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","article-title":"Ductal carcinoma in situ: to treat or not to treat, that is the question","volume":"121","author":"van Seijen","year":"2019","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.01.016_bib4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejso.2017.12.005","article-title":"Navigating treatment controversies for DCIS in the era of genomic profiling and active surveillance trials","volume":"44","author":"Kuerer","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.01.016_bib5","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1055-9965.EPI-18-0976","article-title":"Predictors of an invasive breast cancer recurrence after DCIS: a systematic review and meta-analyses","volume":"28","author":"Visser","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.ejca.2022.01.016_bib6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41379-019-0331-8","article-title":"Ductal carcinoma in situ of the breast: immune cell composition according to subtype","volume":"33","author":"Agahozo","year":"2020","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.ejca.2022.01.016_bib7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","article-title":"Immune escape in breast cancer during in situ to invasive carcinoma transition","volume":"7","author":"Gil Del Alcazar","year":"2017","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.ejca.2022.01.016_bib8","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1172\/JCI125890","article-title":"Stromal integrin alpha11 regulates PDGFR-beta signaling and promotes breast cancer progression","volume":"129","author":"Primac","year":"2019","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.ejca.2022.01.016_bib9","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1016\/j.ajpath.2015.07.004","article-title":"Myoepithelial cell differentiation markers in ductal carcinoma in situ progression","volume":"185","author":"Russell","year":"2015","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.ejca.2022.01.016_bib10","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/jnci\/djy234","article-title":"Impact of epithelial-stromal interactions on peritumoural fibroblasts in ductal carcinoma in situ","volume":"111","author":"Strell","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2022.01.016_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(06)90001-7","article-title":"Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumour development and shaping tumour immunogenicity","volume":"90","author":"Smyth","year":"2006","journal-title":"Adv Immunol"},{"issue":"3","key":"10.1016\/j.ejca.2022.01.016_bib12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/annonc\/mdt556","article-title":"Prognostic value of tumour-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study","volume":"25","author":"Dieci","year":"2014","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2022.01.016_bib13","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1200\/JCO.18.02157","article-title":"Effect of radiotherapy after breast-conserving surgery depending on the presence of tumour-infiltrating lymphocytes: a long-term follow-up of the SweBCG91RT randomized trial","volume":"37","author":"Kovacs","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.01.016_bib14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumour-infiltrating lymphocytes and prognosis: a pooled individual patient Analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.01.016_bib15","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumour-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: big 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.01.016_bib16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13058-020-01364-w","article-title":"Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up","volume":"22","author":"Lundgren","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2022.01.016_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092365","article-title":"TILs immunophenotype in breast cancer predicts local failure and overall survival: analysis in a large radiotherapy trial with long-term follow-up","volume":"12","author":"Millar","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ejca.2022.01.016_bib18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.ejca.2022.01.016_bib19","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1200\/JCO.2017.72.7263","article-title":"Response to radiotherapy after breast-conserving surgery in different breast cancer\u00a0subtypes in the Swedish breast cancer group 91 radiotherapy\u00a0randomized clinical trial","volume":"35","author":"Sjostrom","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.01.016_bib20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-20-3299","article-title":"Immune infiltrate in the primary tumour predicts effect of adjuvant radiotherapy in breast cancer; results from the randomized SweBCG91RT trial","volume":"27","author":"Stenmark Tullberg","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"Pt 2","key":"10.1016\/j.ejca.2022.01.016_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","volume":"52","author":"Dieci","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"32","key":"10.1016\/j.ejca.2022.01.016_bib22","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1200\/JCO.2014.56.2595","article-title":"Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial","volume":"32","author":"Warnberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.01.016_bib23","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3389\/fonc.2020.01486","article-title":"Tumour-infiltrating lymphocytes (TILs) and risk of a second breast event after a ductal carcinoma in situ","volume":"10","author":"Farolfi","year":"2020","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.01.016_bib24","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/his.14181","article-title":"Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score","volume":"77","author":"Komforti","year":"2020","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.ejca.2022.01.016_bib25","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s41379-018-0040-8","article-title":"Prognostic significance of tumour-infiltrating lymphocytes in ductal carcinoma in situ of the breast","volume":"31","author":"Toss","year":"2018","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.ejca.2022.01.016_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/bjs.4878","article-title":"Relationship between\u00a0hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ","volume":"92","author":"Barnes","year":"2005","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.ejca.2022.01.016_bib27","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/annonc\/mdl016","article-title":"Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status","volume":"17","author":"Dowsett","year":"2006","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.01.016_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3892\/mco.2017.1185","article-title":"Effect of Ki-67 assessment in the distribution of breast cancer subtypes: evaluation in a cohort of Latin American patients","volume":"6","author":"Yabar","year":"2017","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.01.016_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13058-020-01267-w","article-title":"Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast","volume":"22","author":"Kim","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2022.01.016_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","article-title":"Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast","volume":"161","author":"Campbell","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"10.1016\/j.ejca.2022.01.016_bib31","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1158\/1078-0432.CCR-17-0743","article-title":"Relationship of the breast ductal carcinoma in situ immune microenvironment with clinicopathological and genetic features","volume":"23","author":"Hendry","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2022.01.016_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/annonc\/mdw623","article-title":"The prevalence and clinical relevance of tumour-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast","volume":"28","author":"Pruneri","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.01.016_bib33","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1218106","article-title":"The ratio of CD8(+)\/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ","volume":"5","author":"Semeraro","year":"2016","journal-title":"OncoImmunology"},{"issue":"10","key":"10.1016\/j.ejca.2022.01.016_bib34","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1245\/s10434-019-07562-x","article-title":"Tumour-infiltrating lymphocytes in a contemporary cohort of women with ductal carcinoma in situ (DCIS)","volume":"26","author":"Darvishian","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2022.01.016_bib35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.breast.2021.07.007","article-title":"Tumour-infiltrating lymphocytes in non-invasive breast cancer: a systematic review and meta-analysis","volume":"59","author":"Caparica","year":"2021","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.ejca.2022.01.016_bib36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.01.016_bib37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumour-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.01.016_bib38","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jnci\/djt067","article-title":"A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast","volume":"105","author":"Solin","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2022.01.016_bib39","article-title":"Evaluating tumour-infiltrating lymphocytes in breast cancer using preoperative MRI-based radiomics","author":"Bian","year":"2021","journal-title":"J Magn Reson Imag"},{"issue":"3","key":"10.1016\/j.ejca.2022.01.016_bib40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jmri.26985","article-title":"Role of breast MRI in the evaluation and detection of DCIS: opportunities and challenges","volume":"52","author":"Greenwood","year":"2020","journal-title":"J Magn Reson Imag"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:35:02Z","timestamp":1778517302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":40,"alternative-id":["S0959804922000375"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.01.016","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}